Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer’s Disease: A Comprehensive Review
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role as caregiver. This debilitating disease reportedly consumes 8% of the total United States healthcare expenditure, with medical and nursing outlays accou...
Saved in:
Main Authors: | Hannah W Haddad, Garett W. Malone, Nicholas J. Comardelle, Arielle E. Degueure, Adam M. Kaye, Alan D. Kaye |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Medical Publishing
2022-01-01
|
Series: | Health Psychology Research |
Online Access: | https://doi.org/10.52965/001c.31925 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review
by: Hannah W. Haddad, et al.
Published: (2022-07-01) -
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
by: Byeong-Hyeon Kim, et al.
Published: (2025-01-01) -
Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
by: Jimin Kim, et al.
Published: (2025-01-01) -
Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist
by: So Yeong Jeong, et al.
Published: (2025-01-01) -
Combination Olanzapine and Samidorphan for the Management of Schizophrenia and Bipolar 1 Disorder in Adults: A Narrative Review
by: Hannah W. Haddad, et al.
Published: (2022-04-01)